Skip to main content
ERAS
NASDAQ Life Sciences

Erasca Secures Worldwide Rights for Promising ERAS-0015 Pan-RAS Drug, Expanding Market to China

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$15.9
Mkt Cap
$4.879B
52W Low
$1.01
52W High
$16
52W Position info
1474% above low
Off High info
at 52W high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

ERAS has more than doubled off its 52-week low of $1.01.

Summary

Erasca has exercised its option to secure worldwide rights for its pan-RAS molecular glue, ERAS-0015, by expanding its existing license agreement with Joyo Pharmatech to include China, Hong Kong, and Macau. This strategic move grants Erasca exclusive global rights for ERAS-0015, enabling a unified worldwide development and commercialization strategy. The company emphasizes promising early clinical data for ERAS-0015, positioning it as a potential best-in-class RAS-targeting agent. Securing these rights significantly expands the total addressable market and commercial potential for this key pipeline asset. Investors will now watch for initial Phase 1 monotherapy data for ERAS-0015, which is expected in the first half of 2026.

At the time of this announcement, ERAS was trading at $15.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.9B. The 52-week trading range was $1.01 to $16.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ERAS - Latest Insights

ERAS
Nov 20, 2026, 10:40 AM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $14.01
Real-time Price: $13.74 info
Change: -$0.270 (-2%) info
Market Cap: $4.777B info
ERAS
Nov 20, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $13.75
Real-time Price: $13.74 info
Change: -$0.0100 (-0.07%) info
Market Cap: $4.777B info
ERAS
Nov 20, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $13.99
Real-time Price: $13.74 info
Change: -$0.250 (-2%) info
Market Cap: $4.777B info
ERAS
Nov 17, 2026, 6:40 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $13.99
Real-time Price: $13.74 info
Change: -$0.250 (-2%) info
Market Cap: $4.777B info
ERAS
Nov 12, 2026, 4:03 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $15.78
Real-time Price: $13.74 info
Change: -$2.04 (-13%) info
Market Cap: $4.777B info